News and Updates

The Latest KidWell Newsletter Is Here

We've refreshed several sections to make it even easier to quickly find the resources, clinical updates, and educational opportunities that support your practice and the patients and families you serve.

In this issue:

  • Monthly Payer Reports Available — Stay informed with the latest reporting updates and performance targets.
  • KidWell Resources — Learn how the Community Health Education team can support your practice, patients, and community outreach efforts.
  • Surgery Corner — Clinical insights on Blepharitis and Meibomian Gland Dysfunction.
  • Announcements & Highlights — Save the new date for the Annual KidWell Dinner and explore our redesigned Upcoming Meetings at a Glance page featuring upcoming Lunchtime Lecture Series and Q-Connect sessions.
  • Additional Resources — Submitted by Dr. Maria Petrini, this issue includes Measles Guidance for Pediatric Practices along with important resources to help practices educate families and stay informed.
Mother and father on the couch with baby.

Birth to Three Program Provides Crucial Support to Families

Delaware’s Birth to Three Early Intervention Program supports families with infants and toddlers who have or are at risk of developmental delays or disabilities. The program’s mission is to empower parents and caregivers by providing comprehensive resources and services tailored to each child’s unique needs.

Stay Informed About RSV Immunizations for Infants and Young Children

Respiratory syncytial virus (RSV) is a widespread respiratory virus that poses serious health risks for infants and young children. To combat this, the Centers for Disease Control and Prevention (CDC) now recommends RSFP immunization to help prevent severe RSV disease. This can be achieved through maternal vaccination or the administration of the RSV monoclonal antibody (nirsevimab) to infants.

Father and son talking with doctor
Two children jumping in puddles

FDA Approves Self-Administration of Nasal Spray Influenza Vaccine

In September 2024, the U.S. Food and Drug Administration (FDA) granted approval for FluMist, the nasal spray influenza vaccine, to be administered by individuals themselves or by caregivers. This new option provides a safe and effective alternative of receiving the seasonal influenza vaccine, offering increased convenience and flexibility for families.